



the campaign for
SUSTAINABLE Rx PRICING

June 16, 2026

The Honorable Bill Cassidy, M.D.
Chairman
Senate Committee on Health, Education,
Labor & Pensions
428 Senate Dirksen Office Building
Washington, D.C. 20510

The Honorable Bernie Sanders
Ranking Member
Senate Committee on Health, Education,
Labor & Pensions
428 Senate Dirksen Office Building
Washington, D.C. 20510

Dear Chairman Cassidy and Ranking Member Sanders:

The Campaign for Sustainable Rx Pricing (CSRxP) commends you for your bipartisan work to make prescription drugs more affordable and accessible for patients. We very much appreciate and applaud your leadership in seeking to address this critically important issue that impacts millions of Americans every day.

CSRxP is a broad-based nonpartisan coalition of leaders committed to fostering an informed discussion on sustainable drug pricing. Our member organizations represent consumers, employers, health plans, hospitals, nurses, pharmacists, pharmacy benefit companies, and physicians. Our coalition is united behind one goal: to lower the cost of prescription drugs for patients. We are committed to developing bipartisan, market-based solutions that promote competition, improve affordability, and enhance list price transparency while maintaining patient access to innovative medications that improve health outcomes and save lives. We believe innovation and affordability must go hand in hand.

Prescription drug prices are not sustainable for U.S. patients, families, taxpayers, businesses, and our economy as whole. Twenty-four cents of every health care dollar go toward prescription drugs – with drugs contributing more to health care costs than any other type of health care service.¹ **Big Pharma’s anti-competitive and price-gouging practices have led the Food and Drug Administration (FDA) to assert that “patient affordability crisis” now exists, “creating insurmountable financial barriers for many Americans who need these life-saving treatments.”**² Patients and their families simply should not face such financial challenges in obtaining the treatments they need to get well and remain healthy.

Given the unsustainable growth in prescription drug costs, CSRxP applauds the work of the Committee to increase patient access to more affordable biosimilar and generic drugs. Indeed, generics and biosimilars saved consumers and the U.S. healthcare system overall \$467 billion in

¹ AHIP. [Where Does Your Health Care Dollar Go?](#) October 24, 2024.

² FDA. [Fact Sheet: Bringing Lower-Cost Biosimilar Drugs to American Patients.](#) October 29, 2025.



the campaign for
SUSTAINABLE Rx PRICING

2024 alone.³ To that end, we respectfully urge the Committee to advance the following pieces of bipartisan legislation that will encourage the development of lower cost biosimilars and increase access to more affordable generic drugs:

1. **Biosimilar Red Tape Elimination Act (S.1954):** This bipartisan, bicameral legislation introduced by Sen. Lee (R-UT) and cosponsors Sens. Luján (D-NM), Paul (R-KY), and Hassan (D-NH), and Schmitt (R-MO) would eliminate outdated FDA requirements to expedite biosimilar substitution and increase competition from more affordable alternatives to high-priced brand name biologic products.
2. **Medication Affordability and Patent Integrity Act (S.2658):** This bill introduced by Sens. Hassan (D-NH) and Hawley (R-MO) would help to prevent Big Pharma's abuse of the patent system by requiring biopharmaceutical manufacturers to provide consistent and additional information to the FDA and the U.S. Patent and Trademark Office (USPTO) on newly submitted or approved drug applications.
3. **Ensuring Timely Access to Generics Act (S.3014):** This bipartisan legislation introduced by Sens. Shaheen (D-NH) and Collins (R-ME) with cosponsor Sen. Baldwin (D-WI) would help increase competition for generic drugs through improved oversight of the FDA's citizen petition process.

In conclusion, CSRxP again applauds and thanks you for your bipartisan leadership to improve prescription drug affordability for all Americans. Far too often patients experience the unfortunate and unfair choice of either purchasing the life-saving medications they need or paying their bills. Patients and their families should never be presented with such a choice. CSRxP thus looks forward to our continued work with the Committee and Congress to advance bipartisan, market-based solutions that will lower the unsustainable growth in prescription drug costs without imperiling the discovery of innovative breakthrough therapies that improve and advance health for patients.

Sincerely,

Lauren Aronson
Executive Director
Campaign for Sustainable Rx Pricing

³ Association for Accessible Medicines. [2025 U.S. Generic & Biosimilar Medicines Savings Report](#). September 2025.